positively correlated with androgen independent growth, resistance to chemotherapy, and increased risk of metastatic recurrence. Patients with primary tumors with relatively low LXR expression had a maximum recurrence free survival of 80 months compared to patients with high LXR expression of 15 months. LXR expression in a number of PCa cell lines also showed correlation with metastatic potential. The LXR inverse agonist SR9243, a pharmacologically active compound that suppresses LXR transcriptional activity, potently inhibited PCa tumor growth.
INTRODUCTION AND OBJECTIVES:
The tumor-suppressive microRNA miR-138 has been shown to be down-regulated in prostate cancer (PCa) and has been suggested as a direct regulator of alphamethylacyl-CoA racemase (AMACR), which is highly over-expressed in PCa. The aim of this study was to validate the direct interaction of miR-138 with the 3 0 -UTR of AMACR. Furthermore, the influence of miR-138 on the expression of AMACR and selected AMACR regulators was investigated in PCa cells.
METHODS: DU-145, PC-3 and LNCaP PCa cells were transfected with 100 nM of miR-138 mimic or a control construct for 4 h. A specific siRNA targeting AMACR was used as a positive control for the expression knockdown. 48 h after transfection, mRNA and protein expression levels of AMACR and selected AMACR regulators were determined by quantitative PCR and Western Blot, respectively. Luciferase reporter assays were used to verify target and promoter interaction.
RESULTS: A direct interaction of miR-138 with the AMACR-3 0 -UTR was confirmed by using a luciferase reporter assay. Surprisingly, AMACR mRNA and protein expression were up-regulated by up to 125% and 100%, respectively, following transfection of PCa cells with miR-138. In contrast, a specific siRNA targeting AMACR led to a significant reduction of the AMACR mRNA and protein expression by up to 75% in all three PCa cell lines. The lack of any miR-138 binding sites within the AMACR promoter pointed to an indirect mechanism of up-regulation. Subsequently, the effect of miR-138 on selected AMACR regulators including CTNNB1/b-catenin, RELA, SMAD4, SP1 and TCF4 was evaluated. MiR-138 only promoted an up-regulation of CTNNB1 mRNA expression and bcatenin protein levels by up to 75%. Interestingly, a binding site for miR-138 was present within the CTNNB1 promoter. By using a luciferase reporter assay the direct activation of the CTNNB1 promoter by miR-138 was demonstrated, which consequently could contribute to the observed AMACR up-regulation.
CONCLUSIONS: The present findings suggest that miR-138 can indirectly up-regulate AMACR expression via transcriptional induction of CTNNB1 expression, at least in vitro in PCa cells. These results further fortify the function of miRNAs as transcriptional gene activators in addition to their established role as post-transcriptional silencers.
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MP70-16 SEMA3C DRIVES CANCER GROWTH AND TREATMENT RESISTANCE VIA COGNATE LIGAND-INDEPENDENT ACTIVATION
Ario Takeuchi*, Masaki Shiota, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto, Fukuoka, Japan INTRODUCTION AND OBJECTIVES: Our gene expression profiling data identified a member of the secreted class 3 semaphorins, SEMA3C, to be highly expressed in CRPC and AR pathway inhibitorrecurrent tumors. Increased expression of SEMA3C is associated with poor prognosis and tumor progression in a number of cancers. In prostate cancer, SEMA3C promotes cell migration and invasion in vitro and SEMA3C expression is a predictive marker for biochemical recurrence (BCR). Therefore, we investigated whether SEMA3C could be a key growth factor that drives CRPC progression and treatment resistance.
METHODS: The objective of this study was to evaluate SEMA3C as a therapeutic target for advanced prostate cancer and the physiological consequences of loss-and gain-of-function of SEMA3C. The expression of SEMA3C in a tissue microarray representing a total of 280 prostate cancer specimens was evaluated to determine association of SEMA3C expression with castration and treatment resistance. For in vivo orthotopic model, when mice bearing LNCaP tumors reached a tumor volume over 200 mm3 or serum PSA levels reached greater than 75 ng/ml, castration was performed via the scrotum under isoflurane anesthesia. Treatment commenced when PSA recovered to pre-castration levels. Mice were randomized into 4 groups for treatment with SEMA3C ASO or Scr with or without ENZ. For ASO treatment, Scr ASO or SEMA3C ASO was intra-peritoneally injected once daily for 7 days followed by three weekly treatments thereafter. For ENZ treatment, ENZ or vehicle was intragastrically administered once daily 5 days per week.
RESULTS: Here we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and c-MET in a cognate ligand-independent manner. High SEMA3C expression is associated with metastatic castration-resistant prostate cancer (CRPC). SEMA3C promotes cancer growth and castrate resistant progression while SEMA3C inhibition delays CRPC and Enzalutamide-resistant progression. Proteolytic processing of SEMA3C generates a dominant negative sema domain-containing decoy fragment that suppresses cell growth and RTK signaling. Intratumoral lentiviral delivery of this decoy protein inhibits CRPC progression.
CONCLUSIONS: SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.
